Melosus
meloxicam
Marketing authorisation holder:
CP-Pharma Handelsgesellschaft mbH Ostlandring 13
D-31303 Burgdorf Germany
Manufacturer responsible for batch release: Produlab Pharma B.V.
Forellenweg 16
4941 SJ Raamsdonksveer
The Netherlands
Melosus 1.5 mg/ml oral suspension for dogs Meloxicam
Meloxicam 1.5 mg/ml
Sodium benzoate 1.75 mg/ml
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.
Do not use in pregnant or lactating animals.
Do not use in dogs suffering from gastrointestinal disorders such as irritation and haemorrhage,
impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Do not use in cases of hypersensitivity to the active substance or to any of the excipients. Do not use in dogs less than 6 weeks of age.
Typical adverse reactions of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been
reported. In very rare cases haemorrhagic diarrhoea, haematemesis, gastrointestinal ulceration and elevated liver enzymes have been reported.
These adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.
The frequency of adverse reactions is defined using the following convention:
very common (more than 1 in 10 animals treated displaying adverse reactions)
common (more than 1 but less than 10 animals in 100 animals treated)
uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
rare (more than 1 but less than 10 animals in 10,000 animals treated)
very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.
Dogs
Oral use.
To be administered orally either mixed with food or directly into the mouth. Shake well before use.
Initial treatment is a single oral dose of 0.2 mg meloxicam/kg body weight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg body weight.
For longer term treatment, once clinical response has been observed (after ≥ 4 days), the dose of Melosus can be adjusted to the lowest effective individual dose reflecting that the degree of pain and inflammation associated with chronic musculo-skeletal disorders may vary over time.
The suspension can be given using the Melosus measuring syringe provided in the package.
The syringe fits onto the drop dispenser of the bottle and has a kg-body weight scale which corresponds to the maintenance dose. Thus for initiation of the therapy on the first day, twice the maintenance volume will be required.
A clinical response is normally seen within 3-4 days. Treatment should be discontinued after 10 days at the latest if no clinical improvement is apparent.
After each dose, the tip of the syringe should be wiped and the bottle cap screwed back on tightly. The syringe should be stored in the carton box in between uses.
To avoid introduction of external contaminants during use, keep the provided syringes only for this product.
Particular care should be taken with regard to the accuracy of dosing. Please carefully follow the instructions of the veterinarian.
Not applicable.
Keep out of the sight and reach of children.
This veterinary medicinal product does not require any special storage conditions.
Do not use this veterinary medicinal product after the expiry date which is stated on the carton and bottle after EXP. The expiry date refers to the last day of that month.
Shelf life after first opening the container: 6 months.
Special precautions for use in animals
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity.
This product for dogs should not be used in cats as it is not suitable for use in this species. In cats, Melosus 0.5 mg/ml oral suspension for cats should be used.
Pregnancy and Lactation:
Do not use in pregnant or lactating animals.
Interaction with other medicinal products and other forms of interaction:
Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high
protein binding may compete for binding and thus lead to toxic effects. Melosus must not be administered in conjunction with other NSAIDs or glucocorticosteroids.
Incompatibilities:
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously.
Overdose (symptoms, emergency procedures, antidotes):
In case of overdose symptomatic treatment should be initiated.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:
People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product.
In case of accidental ingestion, seek medical advice immediately and show this package leaflet or the label to the physician.
Medicines should not be disposed of via wastewater or household waste.
Ask your veterinary surgeon how to dispose of medicines no longer required. These measures
should help to protect the environment.
Detailed information on this product is available on the website of the European Medicines Agency
10, 25, 50 or 125 ml bottle.
Not all pack sizes may be marketed.
Marketing authorisation holder:
CP-Pharma Handelsgesellschaft mbH Ostlandring 13
D-31303 Burgdorf Germany
Manufacturer responsible for batch release: Produlab Pharma B.V.
Forellenweg 16
4941 SJ Raamsdonksveer
The Netherlands
Melosus 0.5 mg/ml oral suspension for cats and guinea pigs Meloxicam
Meloxicam 0.5 mg/ml
Sodium benzoate 1.75 mg/ml
Cats:
Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures in cats, e.g. orthopaedic and soft tissue surgery.
Alleviation of pain and inflammation in chronic musculo-skeletal disorders in cats.
Guinea pigs:
Alleviation of mild to moderate post-operative pain associated with soft tissue surgery such as male
castration.
Do not use in pregnant or lactating animals.
Do not use in cats suffering from gastrointestinal disorders such as irritation and haemorrhage,
impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
Do not use in cats less than 6 weeks of age.
Do not use in guinea pigs less than 4 weeks of age.
In cats, typical adverse reactions of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported. In very rare cases elevated liver enzymes have been reported.
These adverse reactions are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.
The frequency of adverse reactions is defined using the following convention:
very common (more than 1 in 10 animals treated displaying adverse reactions during)
common (more than 1 but less than 10 animals in 100 animals treated)
uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
rare (more than 1 but less than 10 animals in 10,000 animals treated)
very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.
Cats and guinea pigs
Oral use.
To be administered orally either mixed with food or directly into the mouth. Shake well before use.
Post-operative pain and inflammation following surgical procedures:
After initial treatment with meloxicam solution for injection for cats, continue treatment 24 hours
later with Melosus 0.5 mg/ml oral suspension for cats at a dosage of 0.05 mg meloxicam/kg body weight. The oral follow-up dose may be administered once daily (at 24-hour intervals) for up to four days.
Chronic musculo-skeletal disorders:
Initial treatment is a single oral dose of 0.1 mg meloxicam/kg body weight on the first day.
Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.05 mg meloxicam/kg body weight.
A clinical response is normally seen within 7 days. Treatment should be discontinued after 14 days at the latest if no clinical improvement is apparent.
The suspension can be given using the Melosus measuring syringe provided in the package.
The syringe fits onto the drop dispenser of the bottle and has a kg-body weight scale which corresponds to the maintenance dose. Thus, for initiation of the therapy on the first day, twice the maintenance volume will be required.
After each dose, the tip of the syringe should be wiped and the bottle cap screwed back on tightly. The syringe should be stored in the carton box in between uses.
To avoid introduction of external contaminants during use, keep the provided syringes only for this
product.
Post-operative pain associated with soft tissue surgery:
Initial treatment is a single oral dose of 0.2 mg meloxicam/kg body weight on day 1 (pre-surgery). Treatment is to be continued once daily by oral administration (at 24-hours intervals) at a dose of
0.1 mg meloxicam/kg body weight on day 2 to day 3 (post-surgery).
The dose can, at the discretion of the veterinarian, be titrated up to 0.5 mg/kg in individual cases. The safety of doses exceeding 0.6 mg/kg has, however, not been evaluated in guinea pigs.
The suspension should be given directly into the mouth using a standard 1 ml syringe graduated with ml scale and 0.01 ml increments.
Dose of 0.2 mg meloxicam/kg body weight: 0.4 ml/kg body weight Dose of 0.1 mg meloxicam/kg body weight: 0.2 ml/kg body weight
Use a small container (e.g. a teaspoon) and drop Melosus oral suspension into the container (it is advised to dispense a few drops more than required into the small container). Use a standard 1 ml syringe to draw up Melosus according to the bodyweight of the guinea pig. Administer Melosus with the syringe directly into the mouth of the guinea pig. Wash the small container with water and dry prior to the next use.
Do not use the cat syringe with the kg-body weight scale for guinea pigs.
Particular care should be taken with regard to the accuracy of dosing. Please carefully follow the instructions of the veterinarian.
Not applicable.
Keep out of the sight and reach of children.
This veterinary medicinal product does not require any special storage conditions.
Do not use this veterinary medicinal product after the expiry date which is stated on the carton and bottle after EXP. The expiry date refers to the last day of that month.
Shelf-life after first opening the container: 6 months.
Special precautions for use in animals:
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity.
Post-operative use in cats and guinea pigs:
In case additional pain relief is required, multimodal pain therapy should be considered.
Chronic musculoskeletal disorders in cats:
Response to long-term therapy should be monitored at regular intervals by a veterinarian.
Melosus should not be used following parenteral injection of meloxicam or any other NSAIDs as appropriate dosage regimens for such follow-up treatments have not been established in cats.
Pregnancy and Lactation:
Do not use in pregnant or lactating animals.
Interaction with other medicinal products and other forms of interaction:
Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high
protein binding may compete for binding and thus lead to toxic effects. Melosus must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic veterinary medicinal products should be avoided.
Incompatibilities:
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously.
Overdose (symptoms, emergency procedures, antidotes):
Meloxicam has a narrow therapeutic safety margin in cats and clinical signs of overdose may be seen at relatively small overdose levels.
In case of overdose, adverse reactions, as listed in section 6 "Adverse reactions", are expected to be more severe and more frequent. In the case of overdose symptomatic treatment should be initiated.
In guinea pigs, an overdose of 0.6 mg/kg body weight administered during 3 days followed by a dose of 0.3 mg/kg during 6 additional days did not cause adverse events typical for meloxicam. The safety of doses exceeding 0.6 mg/kg has not been evaluated in guinea pigs.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:
People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal
product.
In case of accidental ingestion, seek medical advice immediately and show this package leaflet or the label to the physician.
Medicines should not be disposed of via wastewater or household waste.
Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.
Detailed information on this product is available on the website of the European Medicines Agency
15 OTHER INFORMATION
5, 10 or 25 ml bottle.
Not all pack sizes may be marketed.